Abstract 581P
Background
Afatinib is an epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) that is widely used to treatfor EGFR-mutated non-small cell lung cancer (NSCLC). The association between afatinib-related adverse events (AEs) and survival outcomes in patients with NSCLC has been rarely reported.
Methods
We retrospectively reviewed treatment-naȉive patients with NSCLC treated with afatinib for ≥1 month at Chang Gung Memorial Hospital. We analyzed the association between different types of AEs and clinical outcomes, including progression-free survival (PFS) and overall survival (OS).
Results
This study included 599 patients. The patients who experienced any grades of AEs had longer OS (median OS = 27.2 vs. 14.0 months, p = 0.019) than those who did not. As for PFS did not differ significantly between these two groups. Regarding the types of AE, the patients with either paronychia (median PFS =, 16.0 vs. 12.4 months, p = 0.011), skin lesions (median PFS =, 15.4 vs. 12.1 months, p = 0.042), or gastrointestinal (GI) symptoms, including nausea/vomiting (median PFS =, 18.8 vs. 14.3 months, p = 0.016), had experienced significantly better PFS than patients without these AEs. In addition, the patients with either paronychia (median OS =, 31.0 vs. 21.0 months, p < 0.001), skin lesions (median OS =, 29.3 vs. 20.9 months, p < 0.001), pruritus (median OS =, 31.6 vs. 24.7 months, p < 0.001), or mucositis/oral ulcers (median OS =, 30.2 vs. 25,5 months, p < 0.023) had showed better OS than patients without these AEs. After adjustment, the patients with experiencing paronychia and GI symptoms had favorable PFS, and those with paronychia, skin lesions, pruritus, or mucositis/oral ulcers had favorable OS.
Conclusions
Patients with NSCLC treated with patients undergoing afatinib and experiencing adverse events (AEs) had favorable survival PFS and OS. In addition, the associations between afatinib-related AEs and survival outcomes were type-dependent.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Chang Gung Medical Foundation - Linkou Chang Gung Memorial Hospital.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
297P - The utilization rate of radiotherapy and chemotherapy for cervical cancer in Indonesia: Optimal versus actual, how far the gap?
Presenter: Charity Kotambunan
Session: Poster Display
Resources:
Abstract
298P - Managing locally advanced cervical cancer: Insights from a tertiary care center and a 3-year follow-up on outcomes
Presenter: Ambedkar Yadala
Session: Poster Display
Resources:
Abstract
299P - Sexual dysfunction assessment in longterm survivors of carcinoma cervix using LENT SOMA scale
Presenter: Niharika Sethi
Session: Poster Display
Resources:
Abstract
300P - Assessing ovarian function in Vietnamese cervical cancer patients who underwent ovary transposition prior to pelvic radiation therapy
Presenter: Cuong Nguyen
Session: Poster Display
Resources:
Abstract
301P - Correlation between cervical cancer recurrence after radiation therapy and vaginal microbiome
Presenter: Xiaoxian Xu
Session: Poster Display
Resources:
Abstract
302P - Expression of ERCC4 gene and its correlation with clinical and pathological parameters in cervical cancer
Presenter: Himanshu Mishra
Session: Poster Display
Resources:
Abstract
303P - Prognostic value of body composition and systemic inflammatory markers in patients with locally advanced cervical cancer following chemoradiotherapy
Presenter: Hui Guo
Session: Poster Display
Resources:
Abstract
305P - A real-world multicenter cohort study of lenvatinib (LEN) plus pembrolizumab (PEM) in Japanese patients with endometrial cancer: Interim analysis of GOGO-EM4 study
Presenter: Yoshikazu Nagase
Session: Poster Display
Resources:
Abstract
306P - Adjuvant treatment and impact on relapse in stage IA uterine papillary serous and clear cell carcinomas: A single center retrospective study
Presenter: Sachin Khurana
Session: Poster Display
Resources:
Abstract
307P - Hormonal therapy vs combination chemotherapy in metastatic leiomyosarcomas: A systematic review
Presenter: Patricia Angel
Session: Poster Display
Resources:
Abstract